CytoDyn
Executives
View the org chart displaying its 13 main executives
Most searched biographies at CytoDyn
Popular executive movements at CytoDyn
- Antonio Migliarese, Chief Financial Officer, will leave the company on Feb. 1, 2024 (posted on January 29 2024).
- Jacob Lalezari, who was Interim Chief Executive Officer, is promoted to Chief Executive Officer (posted on January 29 2024).
- Mitchell Cohen has joined the company as Interim Chief Financial Officer (posted on January 29 2024).
Create your alert
to follow the executive moves at CytoDyn.
Biotechnology
CytoDyn has 2,284 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Karius has just announced a $100 Million fundraising (posted on May 3 2024).
- Transcarent has just announced a $126 Million fundraising (posted on May 2 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (posted on May 2 2024).
Popular contacts in Biotechnology
News
Press releases by CytoDyn
- CytoDyn Announces FDA Has Lifted Clinical Hold
- CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
- CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
- CytoDyn Announces Webcast to Provide Company Update
- CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
- Annual Meeting of Stockholders
- November 2023 Letter to Shareholders
- CytoDyn Announces Company Updates and Investment Community Update Webcast
- CytoDyn Announces President Takes Medical Leave of Absence
- CytoDyn to Hold Webcast to Provide a Company Update
- View more press releases Close
Social media about CytoDyn
- CytoDyn on Wikipedia, Google News & Yahoo Finance
- CytoDyn on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Tanya Urbach 
